ERJ Viewpoint: vascular targeted therapies for fibrotic lung disease – Start of a new era?

Key Points

• This viewpoint explores how vasculopathy contributes to the progression of pulmonary fibrosis and the potential benefits of targeting it.
• Summarizes current evidence on vasculopathy in pulmonary fibrosis.
• Discusses implications of targeting vascular therapies.
• Identifies vasculopathy as a factor in fibrosis progression.
• Suggests that targeting vasculopathy may lead to new therapeutic strategies.